Contributing to global health and well-being through therapies based on new concepts
First written in FY2019. 14 of 20 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 1 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Reframed".
- FY2026ReframedAnnual report
「The Company has adopted “Empower Life Regeneration — Unlocking the potential of life and living through regenerative medicine®” as its purpose, and is focused on developing “regenerative-inducing pharmaceuticals®,” a next-generation pharmaceutical product designed to overcome the challenges associated with conventional regenerative medicine and cell therapy, by making maximum use of the results of joint research with Osaka University and other universities, as well as research conducted at the Collaborative Research Institute for Regenerative-Inducing Medicine.」
In addition to its conventional management philosophy, the Company has adopted “Empower Life Regeneration — Unlocking the potential of life and living through regenerative medicine®” as its purpose, reorganising its messaging to emphasise solving medical and social issues through regenerative-inducing pharmaceuticals®. - FY2025RestatedAnnual report
「Our corporate philosophy is to contribute to the health and well-being of people worldwide by continuing to create therapies based on new concepts, drawing on the results of cutting-edge life-science research, including regenerative-inducing medicines® that harness the body’s intrinsic tissue-repair capabilities.」
The corporate philosophy of continuously creating new treatments based on regenerative-inducing medicines and contributing to global health and well-being has been reaffirmed. - FY2024RestatedAnnual report
「Our corporate philosophy is to contribute to the health and well-being of people worldwide by continuing to create therapies based on new concepts, drawing on the results of cutting-edge life-science research, including regenerative-inducing medicines® that harness the body’s intrinsic tissue-repair capabilities.」
The corporate philosophy of continuously creating new treatments based on regenerative-inducing medicines and contributing to global health and well-being has been reaffirmed. - FY2024-Q3RestatedAnnual report
「Against this backdrop, we believe that delivering regenerative-inducing medicines® to patients worldwide suffering from a range of diseases, including intractable diseases such as epidermolysis bullosa, as an innovative regenerative-medicine technology designed to overcome the many challenges associated with transplantation and conventional regenerative medicine, represents StemRIM’s social mission.」
The company's social mission of delivering regenerative-inducing medicines to patients with various diseases has been reaffirmed. - FY2024-Q1RestatedAnnual report
「Against this backdrop, we believe that delivering regenerative-inducing medicines® to patients worldwide suffering from a range of diseases, including intractable diseases such as epidermolysis bullosa, as an innovative regenerative-medicine technology designed to overcome the many challenges associated with transplantation and conventional regenerative medicine, represents StemRIM’s social mission.」
The company's social mission of delivering regenerative-inducing medicines to patients with various diseases has been reaffirmed. - FY2023ReframedAnnual report
「Under the corporate philosophy of “Overcoming intractable diseases through regenerative induction,” we have worked to develop regenerative-inducing medicines®, next-generation pharmaceuticals designed to overcome the limitations of conventional regenerative medicine and cell therapy, while making maximum use of the results of joint research with universities including Osaka University and research conducted at the Collaborative Research Institute for Regenerative Induction Medicine.」
The sustainability disclosure uses the separate corporate-philosophy wording “Overcoming intractable diseases through regenerative induction,” placing greater emphasis on overcoming intractable diseases than the previous corporate philosophy. - FY2023-Q1RestatedAnnual report
「StemRIM believes that its social mission is to deliver regenerative-inducing medicines to patients worldwide suffering from a wide range of diseases, including intractable diseases such as epidermolysis bullosa. These medicines achieve regenerative medicine by inducing the accumulation of mesenchymal stem cells within the patient's own body through drug administration, without using cells cultured and processed outside the body, and represent an innovative regenerative medicine technology that overcomes many of the challenges associated with transplantation and conventional regenerative medicine.」
The company's social mission of delivering regenerative-inducing medicines to patients with various intractable diseases has been reaffirmed. - FY2022RestatedAnnual report
「Our corporate philosophy is to contribute to global health and well-being by continuously creating treatments based on new concepts, drawing on the results of cutting-edge life sciences research, including regenerative-inducing medicines that harness the body's inherent tissue-repair capabilities.」
The corporate philosophy of continuously creating new treatments based on regenerative-inducing medicines and contributing to global health and well-being has been reaffirmed. - FY2022-Q1RestatedAnnual report
「Against this backdrop, StemRIM believes that its social mission is to deliver regenerative-inducing medicines to patients worldwide suffering from a wide range of diseases, including intractable diseases such as epidermolysis bullosa. These medicines achieve regenerative medicine by inducing the accumulation of mesenchymal stem cells within the patient's own body through drug administration, without using cells cultured and processed outside the body, and represent an innovative regenerative medicine technology that overcomes many of the challenges associated with transplantation and conventional regenerative medicine.」
The company's social mission of delivering regenerative-inducing medicines to patients with various diseases has been reaffirmed. - FY2021RestatedAnnual report
「Our corporate philosophy is to contribute to global health and well-being by continuously creating treatments based on new concepts, drawing on the results of cutting-edge life sciences research, including regenerative-inducing medicines that harness the body's inherent tissue-repair capabilities.」
The corporate philosophy of continuously creating new treatments based on regenerative-inducing medicines and contributing to global health and well-being has been reaffirmed. - FY2021-Q3RestatedAnnual report
「StemRIM believes that its social mission is to deliver regenerative-inducing medicines to patients worldwide suffering from a wide range of diseases, including intractable diseases such as epidermolysis bullosa. These medicines achieve regenerative medicine by inducing the accumulation of mesenchymal stem cells within the patient's own body through drug administration, without using cells cultured and processed outside the body, and represent an innovative regenerative medicine technology that overcomes many of the challenges associated with transplantation and conventional regenerative medicine.」
The company's social mission of delivering regenerative-inducing medicines to patients with various diseases has been reaffirmed. - FY2021-Q2RestatedAnnual report
「StemRIM believes that its social mission is to deliver regenerative-inducing medicines to patients worldwide suffering from a wide range of diseases, including intractable diseases such as epidermolysis bullosa. These medicines achieve regenerative medicine by inducing the accumulation of mesenchymal stem cells within the patient's own body through drug administration, without using cells cultured and processed outside the body, and represent an innovative regenerative medicine technology that overcomes many of the challenges associated with transplantation and conventional regenerative medicine.」
The company's social mission of delivering regenerative-inducing medicines to patients with various diseases has been reaffirmed. - FY2021-Q1RestatedAnnual report
「StemRIM believes that its social mission is to deliver regenerative-inducing medicines to patients worldwide suffering from a wide range of diseases, including intractable diseases such as epidermolysis bullosa. These medicines achieve regenerative medicine by inducing the accumulation of mesenchymal stem cells within the patient's own body through drug administration, without using cells cultured and processed outside the body, and represent an innovative regenerative medicine technology that overcomes many of the challenges associated with transplantation and conventional regenerative medicine.」
The company's fundamental mission of delivering new regenerative medicine to patients with various diseases through regenerative-inducing medicines has been reaffirmed. - FY2020-Q3RestatedAnnual report
「Since its founding, the company has pursued research and development aimed at realizing regenerative-inducing medicines.」
The basic policy of pursuing research and development toward the realization of regenerative-inducing medicines has been reaffirmed. - FY2020-Q2RestatedAnnual report
「Since its founding, the company has pursued research and development aimed at realizing regenerative-inducing medicines.」
The company's basic policy of pursuing research and development centered on regenerative-inducing medicines has been reaffirmed. - FY2019First statedAnnual report
「Our corporate philosophy is to contribute to global health and well-being by continuously creating treatments based on new concepts, drawing on the results of cutting-edge life sciences research, including regenerative-inducing medicines that harness the body's inherent tissue-repair capabilities.」
The company has adopted as its corporate philosophy the continuous creation of new treatments centered on regenerative-inducing medicines.